Lipigon Pharmaceuticals (LPGO.ST)

Executive Summary

Lipigon Pharmaceuticals is a Swedish biotech company founded in 2015 and headquartered in Umeå, specializing in developing novel therapeutics for lipid metabolism disorders. The company leverages its deep expertise in blood lipid biology to create small molecule and RNA-based drugs. Its lead candidate, Lipisense, is an RNA-based antisense drug designed to lower triglycerides in patients with severe hypertriglyceridemia, a condition with high unmet medical need and significant cardiovascular risk. Lipisense has the potential to offer a differentiated mechanism of action compared to existing therapies such as fibrates and omega-3 fatty acids. Lipigon is currently advancing Lipisense through clinical development, with early-phase data suggesting a favorable safety and efficacy profile. The company is also exploring additional indications and pipeline candidates targeting other lipid metabolism disorders. As a publicly traded entity on the Spotlight Stock Market (ticker: LPGO.ST), Lipigon remains focused on delivering clinical milestones and securing partnerships to support its development programs. Key upcoming events include the release of Phase 2b data for Lipisense, which will be critical for advancing the program into pivotal trials. With a strong scientific foundation and a clear focus on high-need lipid disorders, Lipigon represents a compelling investment opportunity in the precision medicine space.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b Top-Line Data for Lipisense in Severe Hypertriglyceridemia60% success
• TBDLicensing or Partnership Deal for Lipisense in Asia/Europe40% success
• H2 2026Upsized Financing Round to Fund Phase 3 Preparation70% success